1073973-23-5

Basic information

• Product Name: (S)-4-bromo-2-fluoro-6-((tetrahydrofuran-3-yl)amino)benzonitrile
• Synonyms: (S)-4-bromo-2-fluoro-6-((tetrahydrofuran-3-yl)amino)benzonitrile
• CAS NO: 1073973-23-5
• Molecular Weight: 285.116
• Mol File: 1073973-23-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (S)-4-bromo-2-fluoro-6-((tetrahydrofuran-3-yl)amino)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-bromo-2-fluoro-6-((tetrahydrofuran-3-yl)amino)benzonitrile(1073973-23-5)
• EPA Substance Registry System: (S)-4-bromo-2-fluoro-6-((tetrahydrofuran-3-yl)amino)benzonitrile(1073973-23-5)

Safety Data

• Hazardous Substances Data: 1073973-23-5(Hazardous Substances Data)

Upstream product

• 204512-95-8 (3S)-tetrahydrofuran-3-amine hydrochloride 
• 123843-67-4 4-bromo-2,6-difluorobenzonitrile 
• 104530-80-5 (S)-(-)-tetrahydro-3-furylamine p-toluenesulfonate salt 
• 104530-79-2 (S)-tetrahydrofuran-3-yl-amine 

Downstream Products

• 1279094-40-4 C₂₄H₂₈FN₃O₃ 
• 1279096-14-8 C₂₄H₂₆FN₃O₂ 
• 1279096-15-9 C₂₃H₂₄FN₃O₃ 
• 1279094-39-1 C₂₃H₂₆FN₃O₄ 
• 1595027-61-4 2-fluoro-6-(((3S)-tetrahydrofuran-3yl)amino)-4-(2,7,7-trimethyl-5-oxo-decahydro-1H-pyrido[3,4-b]indol-9(9aH)-yl)benzamide 
• 1073973-98-4 C₁₁H₁₂BrFN₂O₂ 
• 1073973-84-8 2-fluoro-6-((S)-tetrahydro-furan-3-ylamino)-4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indol-1-yl)-benzonitrile 
• 1073973-24-6 2-fluoro-6-((S)-tetrahydro-furan-3-ylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzonitrile 
• 1073973-79-1 4-(3-ethyl-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-2-fluoro-6-(tetrahydro-furan-3-ylamino)-benzonitrile 

Relevant articles and documents

Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as huntington's disease

A structure-based drug design strategy was used to optimize a novel benzolactam series of HSP90α/β inhibitors to achieve >1000-fold selectivity versus the HSP90 endoplasmic reticulum and mitochondrial isoforms (GRP94 and TRAP1, respectively). Selective HS

HSP90 MODULATING COMPOUNDS, COMPOSITIONS, METHODS AND USES

The invention relates to therapeutic compounds which bind to HSP90, said compounds containing a benzamide group bound to a tricyclic condensed ring system via the nitrogen atom of a pyrrole located in the center of the condensed system. The compounds disclosed herein bind HSP90 and alter the chaperoning capability of HSP90 proteins. Intermediate benzonitrile compounds which are precursors to the benzamide compounds are also disclosed. The invention also relates to pharmaceutical compositions comprising these compounds, and methods of treating diseases and disorders such as cancer, autoimmune diseases and other diseases.